EP Patent

EP1532980A1 — N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes

Assigned to Novo Nordisk AS · Expires 2005-05-25 · 21y expired

What this patent protects

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is benefical, such as diabetes. The compounds are of the general formula (…

USPTO Abstract

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is benefical, such as diabetes. The compounds are of the general formula (I) wherein B is and A is heteroaryl as defined in the claims.

Drugs covered by this patent

Patent Metadata

Patent number
EP1532980A1
Jurisdiction
EP
Classification
—
Expires
2005-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.